Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.
Medtronic reports Q3 2024 sales of $8.1 billion, driven by major product approvals in diabetes, cardiac rhythm management, and more. Medtronic's move to exit the ventilator product line.
FDA greenlights AstraZeneca's Tagrisso combo for advanced EGFRm NSCLC. FLAURA2 Phase 3 trial results reveal a 38% reduction in progression risk with Tagrisso plus chemo, outperforming monotherapy. AstraZeneca's datopotamab deruxtecan awaits FDA decision in Q4 2024 for nonsquamous NSCLC.
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000's Phase 3 trial this year, reducing late-stage risks.
Inventiva announces a voluntary pause in NATiV3 Phase 3 trial of lanifibranor for NASH due to a treatment-related SUSAR. Screening and randomization halted temporarily.